Patents by Inventor Eric M. Poeschla
Eric M. Poeschla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10456480Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: GrantFiled: July 30, 2018Date of Patent: October 29, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: Eric M. Poeschla, Roman A. Barraza
-
Publication number: 20180326016Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: ApplicationFiled: July 30, 2018Publication date: November 15, 2018Applicant: Mayo Foundation for Medical Education and ResearchInventors: Eric M. Poeschla, Roman A. Barraza
-
Patent number: 10058597Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: GrantFiled: June 20, 2016Date of Patent: August 28, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Eric M. Poeschla, Roman A. Barraza
-
Patent number: 9981019Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.Type: GrantFiled: July 28, 2016Date of Patent: May 29, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, Jr., Meghan McGee Painter, Eric M. Poeschla
-
Publication number: 20170014490Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.Type: ApplicationFiled: July 28, 2016Publication date: January 19, 2017Inventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, Jr., Meghan McGee Painter, Eric M. Poeschla
-
Publication number: 20160287676Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: ApplicationFiled: June 20, 2016Publication date: October 6, 2016Inventors: Eric M. Poeschla, Roman A. Barraza
-
Patent number: 9421242Abstract: This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods for increasing expression of an Oas gene family polypeptide, an Ifit gene family polypeptide, an Isg15 polypeptide, a Rig-1 polypeptide, a Mda5 polypeptide, and a Mx1 polypeptide in mammals using a lentiviral vector comprising nucleic acid encoding a picornavirus 3Dpol polypeptide (or a fragment thereof) are provided.Type: GrantFiled: January 15, 2014Date of Patent: August 23, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: Moses Rodriguez, Allan J. Bieber, Arthur E. Warrington, Jr., Meghan McGee Painter, Eric M. Poeschla
-
Patent number: 9393322Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: GrantFiled: October 9, 2014Date of Patent: July 19, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: Eric M. Poeschla, Roman A. Barraza
-
Publication number: 20150031757Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: ApplicationFiled: October 9, 2014Publication date: January 29, 2015Applicant: Mayo Foundation for Medical Education and ResearchInventors: Eric M. Poeschla, Roman A. Barraza
-
Patent number: 8871733Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: GrantFiled: September 21, 2012Date of Patent: October 28, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Eric M. Poeschla, Roman A. Barraza
-
Patent number: 8299043Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: GrantFiled: April 27, 2007Date of Patent: October 30, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Eric M. Poeschla, Roman A. Barraza
-
Publication number: 20090297480Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.Type: ApplicationFiled: April 27, 2007Publication date: December 3, 2009Inventors: Eric M. Poeschla, Roman A. Barraza
-
Patent number: 6555107Abstract: The invention provides non-primate lentiviral vectors, packaging cells and packaging plasmids based, for example, on feline and ungulate retroviruses. In particular, the packaging plasmids are designed for expression in human cells (which are also used as packaging cells). The vectors of the invention transduce human cells, including difficult to target non-dividing cells of the hematopoietic and nervous system, in vitro and in vivo. The vectors are suitable for general gene transfer to these cells and for gene therapy to treat conditions mediated by these non-dividing cells including cancer and HIV infection.Type: GrantFiled: April 17, 2001Date of Patent: April 29, 2003Assignee: The Regents of the University of CaliforniaInventors: Eric M. Poeschla, David J. Looney, Flossie Wong-Staal
-
Publication number: 20030012769Abstract: The invention provides non-primate lentiviral vectors, packaging cells and packaging plasmids based, for example, on feline and ungulate retroviruses. In particular, the packaging plasmids are designed for expression in human cells (which are also used as packaging cells). The vectors of the invention transduce human cells, including difficult to target non-dividing cells of the hematopoietic and nervous system, in vitro and in vivo. The vectors are suitable for general gene transfer to these cells and for gene therapy to treat conditions mediated by these non-dividing cells including cancer and HIV infection.Type: ApplicationFiled: December 21, 2001Publication date: January 16, 2003Inventors: Eric M. Poeschla, David J. Looney, Flossie Wong-Staal
-
Publication number: 20010016347Abstract: The invention provides non-primate lentiviral vectors, packaging cells and packaging plasmids based, for example, on feline and ungulate retroviruses. In particular, the packaging plasmids are designed for expression in human cells (which are also used as packaging cells). The vectors of the invention transduce human cells, including difficult to target non-dividing cells of the hematopoietic and nervous system, in vitro and in vivo. The vectors are suitable for general gene transfer to these cells and for gene therapy to treat conditions mediated by these non-dividing cells including cancer and HIV infection.Type: ApplicationFiled: April 17, 2001Publication date: August 23, 2001Inventors: Eric M. Poeschla, David J. Looney, Flossie Wong-Staal
-
Patent number: 6235881Abstract: Novel HIV-2 proviruses, molecular clones, nucleic acids, polypeptides, viruses and viral components are described. The use of these compositions as components of diagnostic assays, as immunological reagents, as vaccines, as components of packaging cells, cell transduction vectors, and as gene therapy vectors is also described.Type: GrantFiled: February 23, 1999Date of Patent: May 22, 2001Assignee: The Regents of the University of CaliforniaInventors: Gunter Kraus, Flossie Wong-Staal, Randy L. Talbott, Eric M. Poeschla
-
Patent number: 5883081Abstract: Novel HIV-2 proviruses, molecular clones, nucleic acids, polypeptides, viruses and viral components are described. The use of these compositions as components of diagnostic assays, as immunological reagents, as vaccines, as components of packaging cells, cell transduction vectors, and as gene therapy vectors is also described.Type: GrantFiled: June 7, 1996Date of Patent: March 16, 1999Assignee: The Regents of the University of CaliforniaInventors: Gunter Kraus, Flossie Wong-Staal, Randy Talbott, Eric M. Poeschla
-
Patent number: 5650309Abstract: Vectors are provided which stably transduce cells, rendering the cells resistant to a target virus. The vectors are amplified upon infection of the cell by a target virus, and spread throughout an infected host in response to infection by the target virus.Type: GrantFiled: May 16, 1995Date of Patent: July 22, 1997Assignee: The Regents of the University of CaliforniaInventors: Flossie Wong-Staal, Michael Mamounas, Eric M. Poeschla, Gunter Kraus, Mark Leavitt